相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
Eskil Eskilsson et al.
NEURO-ONCOLOGY (2018)
Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
D. Westover et al.
ANNALS OF ONCOLOGY (2018)
Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development
Zev A. Binder et al.
CANCER CELL (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice
Jing Wang et al.
PHARMACOLOGICAL RESEARCH (2018)
High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF-κB activation and predicts poor prognosis in human glioma
Chenglong Yue et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma
Gao Guo et al.
NATURE NEUROSCIENCE (2017)
The structure-guided discovery of osimertinib: the first US FDA approved mutant selective inhibitor of EGFR T790M
Sam Butterworth et al.
MEDCHEMCOMM (2017)
A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma
Madan M. Kwatra
CURRENT CANCER DRUG TARGETS (2017)
SRPX2 Enhances the Epithelial-Mesenchymal Transition and Temozolomide Resistance in Glioblastoma Cells
Haitao Tang et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2016)
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma
Yufang Ma et al.
CLINICAL CANCER RESEARCH (2016)
PD-L1 expression and prognostic impact in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2016)
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
Tikvah K. Hayes et al.
CANCER CELL (2016)
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
Peter Ballard et al.
CLINICAL CANCER RESEARCH (2016)
CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways
Xuejiao Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Epidermal growth factor receptor targeting and challenges in glioblastoma
Amy Haseley Thorne et al.
NEURO-ONCOLOGY (2016)
Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity
Mingshan Niu et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2015)
Plumbagin inhibits growth of gliomas in vivo via suppression of FOXM1 expression
Mingshan Niu et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2015)
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
Yuliana Yosaatmadja et al.
JOURNAL OF STRUCTURAL BIOLOGY (2015)
EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling
Feng Liu et al.
MOLECULAR CELL (2015)
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M
Kenneth S. Thress et al.
NATURE MEDICINE (2015)
Toward precision medicine in glioblastoma: the promise and the challenges
Michael D. Prados et al.
NEURO-ONCOLOGY (2015)
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Pasi A. Jaenne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Current therapeutic advances targeting EGFR and EGFRvIII in glioblastoma
Emily Padfield et al.
FRONTIERS IN ONCOLOGY (2015)
EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma
L. Li et al.
ONCOGENE (2015)
OPINION Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma
Frank B. Furnari et al.
NATURE REVIEWS CANCER (2015)
Autophagy contributes to gefitinib-induced glioma cell growth inhibition
Cheng-Yi Chang et al.
EXPERIMENTAL CELL RESEARCH (2014)
Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
M. Raymond V. Finlay et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
RTOG 0211: A Phase 1/2 Study of Radiation Therapy With Concurrent Gefitinib for Newly Diagnosed Glioblastoma Patients
Arnab Chakravarti et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Differential Sensitivity of Glioma-versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors
Igor Vivanco et al.
CANCER DISCOVERY (2012)
Oncogenic EGFR Signaling Activates an mTORC2-NF-κB Pathway That Promotes Chemotherapy Resistance
Kazuhiro Tanaka et al.
CANCER DISCOVERY (2011)
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sith Sathornsumetee et al.
NEURO-ONCOLOGY (2010)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Michael D. Prados et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Epidermal growth factor receptor inhibitors in neuro-oncology: Hopes and disappointments
Alba A. Brandes et al.
CLINICAL CANCER RESEARCH (2008)
分享论文
